We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,623

Proposed new regulations for PMNOC proceedings and CSPs
  • Bereskin & Parr LLP
  • Canada
  • August 2 2017

On July 15 2017 the government published proposed new regulations to change the procedure under the Patented Medicines (Notice of Compliance


Methods of medical treatment and dosage claims
  • Gowling WLG
  • Canada
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada


Global Government Solutions 2016: Mid-Year Outlook
  • K&L Gates
  • Australia, Canada, European Union, Germany, Global, United Kingdom, USA
  • July 1 2016

As we issue this 2016 Mid-Year Outlook, the global community has begun to wrestle in earnest with the momentous political, economic, and doing


Cialis Canadian Patent Knocks Out Double Patenting Challenge
  • Bereskin & Parr LLP
  • Canada
  • January 20 2017

Eli Lilly's Canadian patent on treatment of erectile dysfunction with Cialis continues to defy all challengers. A recent appeal case originated from


Pharma and Biologics Disputes in CanadaBig Changes for Big and Small Molecule Litigation
  • Bennett Jones LLP
  • Canada
  • July 20 2017

The patent litigation that propels generic and biosimilar products to market will soon change dramatically. July 15, 2017, marked the release of


December 2016 International Trade Compliance
  • Baker McKenzie
  • OECD, United Kingdom, USA, Australia, Canada, European Union, Global
  • December 12 2016

On 29 November 2016, the WTO reported that most WTO members welcomed Ecuador’s efforts to lower its import surcharge rates and reduce the number of


Intellectual Property Weekly Abstracts Bulletin Week Of July 31, 2017
  • Borden Ladner Gervais LLP
  • Canada
  • August 2 2017

This is an appeal of the Federal Court’s decision allowing Gilead’s claim to invalidate Idenix’s ‘191 Patent on the grounds of insufficient disclosure


Teva awarded section 8 damages regarding pregabalin and olanzapine
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • April 27 2017

On March 30 and April 4, 2017, the Federal Court released two decisions on the merits under section 8 of the Patented Medicines (Notice of


Prohibition order denied against Apotex for generic tenofovir disoproxilemtricitabine
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • October 31 2016

The Federal Court dismissed Gilead's prohibition application against Apotex for its tenofovir disoproxil fumarate (TDF) and emtricitabine fixed dose


Amendments to Canada’s patent linkage provisions relating to generic and biosimilar market approval
  • DLA Piper LLP
  • Canada
  • July 17 2017

On July 14, 2017, long-awaited amendments to Canada's patent linkage provisions (the Patented Medicines (Notice of Compliance) Regulations